Actinium Therapy for Late-stage Aggressive Sarcomas

To be considered for this study, you need to be at least 18 years old and have soft tissue sarcoma that has either come back after treatment or hasn't responded well to previous treatments. Your cancer must be visible on scans, and a special type of PET scan needs to show that it is active in a certain way.

You also need to be in generally good health, meaning your blood tests and organ functions (like your kidneys and liver) need to be working well. If you are a man or woman who could have children, you must agree to use two reliable forms of birth control during the study and for some time afterward.

There are also some reasons why you might not be able to join. For example, if you've had certain types of radiation therapy, another type of similar treatment recently, or major surgery within the last two weeks. Certain heart conditions or other serious uncontrolled health issues might also prevent you from taking part.

If you decide to take part in this study, you will receive the study drug, RTX-2358, as an injection once every eight weeks. You might have up to six injections, with a target of four, over about a year, depending on how your body reacts and how your cancer responds.

During the first treatment cycle, you'll visit the clinic three times in the first week, and then once a week for the remaining seven weeks of that cycle for check-ups and tests. For cycles two to six, you will visit the clinic once every two weeks for your appointments and follow-up tests. After your treatment period, you will have long-term follow-up visits, either in person or remotely, every six months for up to five years, to keep track of your health and the cancer.